<!doctype html>
<html lang="en"><head>
<meta charset="utf-8"/><meta name="viewport" content="width=device-width,initial-scale=1"/>
<title>NCT04940286 – Phase II Study of Neoadjuvant Gemcitabine, Nab-paclitaxel, Durvalumab (MEDI4736) (Anti-PD-L1), and Oleclumab (Anti-CD73) in the Treatment of Resectable/Borderline Resectable Primary Pancreatic Adenocarcinoma</title>
<link rel="stylesheet" href="../assets/styles.css"/>
</head><body><div class="container">
  <a href="../index.html">← Back to index</a>
  <h1>NCT04940286</h1>

  <div class="card">
    <div><strong>Title:</strong> Phase II Study of Neoadjuvant Gemcitabine, Nab-paclitaxel, Durvalumab (MEDI4736) (Anti-PD-L1), and Oleclumab (Anti-CD73) in the Treatment of Resectable/Borderline Resectable Primary Pancreatic Adenocarcinoma</div>
    <div class="meta"><strong>Year:</strong>  &nbsp; <strong>Authors:</strong> —</div>
    <div class="meta"><a href="https://clinicaltrials.gov/study/NCT04940286" target="_blank" rel="noopener">Registry page</a></div>
  </div>

  <div class="card">
    <h3>Documents (from CSV)</h3>
    <ul class="list">
      <li>📄 <a href="https://cdn.clinicaltrials.gov/large-docs/86/NCT04940286/ICF_000.pdf" target="_blank" rel="noopener">Informed Consent Form</a></li>
    </ul>
  </div>

  <div class="card">
    <h3>Preview</h3>
    <iframe class="pdf-iframe" src="https://mozilla.github.io/pdf.js/web/viewer.html?file=https://cdn.clinicaltrials.gov/large-docs/86/NCT04940286/ICF_000.pdf"></iframe>
  </div>
</div></body></html>
